Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019046775) INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/046775 International Application No.: PCT/US2018/049186
Publication Date: 07.03.2019 International Filing Date: 31.08.2018
IPC:
C07D 471/04 (2006.01) ,C07D 487/04 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
HATCHER, John M. [US/US]; US
DANA-FARBER CANCER INSTITUTE, INC. [US/US]; 450 Brookline Avenue Boston, Massachusetts 02215, US
Inventors:
HATCHER, John M.; US
GRAY, Nathanael S.; US
JANG, Jaebong; US
DE CLERCQ, Dries; US
JANNE, Pasi; US
SAXON, James A.; US
ECK, Michael; US
Agent:
ERLACHER, Heidi; US
CHEN, Chen; US
Priority Data:
62/552,53131.08.2017US
Title (EN) INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE
(FR) INHIBITEURS D'EGFR ET/OU DE HER2 ET PROCÉDÉS D'UTILISATION
Abstract:
(EN) The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.
(FR) L'invention concerne un composé de formule X : qui module l'activité de HER2 et/ou d'un mutant de celui-ci, et/ou EGFR et/ou un mutant de celui-ci, une composition pharmaceutique comprenant le composé, et un procédé de traitement ou de prévention d'une maladie dans laquelle HER2 et/ou un mutant de celui-ci, et/ou EGFR et/ou un mutant de celui-ci, est impliqué.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)